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ABSTRACT
Aims/Introduction: Flash and continuous glucose monitoring systems are becoming
prevalent in clinical practice. We directly compared a flash glucose monitoring system
(FreeStyle Libre Pro [FSL-Pro]) with a continuous glucose monitoring system (iPro2) in
patients with diabetes mellitus.
Materials and Methods: Glucose concentrations were simultaneously measured using
the FSL-Pro, iPro2 and self-monitoring blood glucose in 10 patients with diabetes mellitus,
and agreement among them was assessed.
Results: Parkes error grid analysis showed that the 92.9 and 7.1% of glucose values
measured using the FSL-Pro fell into areas A and B, respectively, and that 96.3, 2.8 and
0.9% of those determined using iPro2 fell into areas A, B and C, respectively. The median
absolute relative differences compared with self-monitoring blood glucose were 8.1%
(3.9–12.7%) and 5.0% (2.6–9.1%) for the FSL-Pro and iPro2, respectively. Analysis of 5,555
paired values showed a close correlation between FSL-Pro and iPro2 glucose values
(q = 0.96, P < 0.01). Notably, 65.3% of all glucose values were lower for the FSL-Pro than
the iPro2. Median glucose values also decreased by 3.3% for the FSL-Pro compared with
the iPro2 (177.0 [133.0–228.0] vs 183.0 [145.0–230.0] mg/dL, P < 0.01). The difference in
glucose values between the two systems was more pronounced in hypoglycemia. The
median absolute relative difference between FSL-Pro and iPro2 during hypoglycemia was
much larger than that during euglycemia and hyperglycemia.
Conclusions: Both the FSL-Pro and iPro2 systems are clinically acceptable, but glucose
values tended to be lower when measured using the FSL-Pro than the iPro2. Agreement
was not close between these systems during hypoglycemia.
INTRODUCTION
Regular self-monitoring of blood glucose (SMBG) is required to
improve blood glucose control in patients with types 1 and 2
diabetes mellitus requiring insulin therapy1,2. In contrast, evi-
dence of the effectiveness of self-monitoring is controversial for
patients with type 2 diabetes mellitus managed without insu-
lin3,4. Although an integral part of treatment, SMBG is clinically
limited, as the overall daily blood glucose proﬁle is not cap-
tured, and postprandial hyperglycemia or nocturnal hypo-
glycemia is often underestimated5. Furthermore, SMBG is
accompanied by the burden and pain associated with multiple
measurements of capillary blood glucose using ﬁngersticks.
Continuous glucose monitoring systems (CGMS) measure
interstitial ﬂuid glucose concentrations (ISFG) throughout the
day and provide information that is unattainable by SMBG6.
Several devices have been developed to measure ISFG7. The
iPro2 is a professional CGMS that enables the collection of
ISFG proﬁles for up to 7 days of wear per sensor. The iPro2
requires calibrations with SMBG four times daily to calibrate
ISFG. The FreeStyle Libre Pro (FSL-Pro) is a professional ﬂash
glucose monitoring system (FGMS) that was approved in Japan
after the iPro2. This system can monitor ISFG for 14
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consecutive days of wear per sensor. Unlike the iPro2 CGMS,
the FSL-Pro is factory-calibrated for ISFG, meaning that
patients do not need to measure capillary glucose concentra-
tions for calibration. The application of the iPro2 and FSL-Pro
systems in clinical practice has increased, and they help to
understand postprandial hyperglycemia and nocturnal hypo-
glycemia, which provides beneﬁts to many patients with
diabetes mellitus.
Here, ISFG was simultaneously measured in patients with
diabetes mellitus requiring insulin therapy using the FSL-Pro
and iPro2 and agreement between them was assessed. To the
best of our knowledge, these systems have not yet been com-
pared in hospitalized patients.
METHODS
The present study enrolled patients with diabetes mellitus
requiring insulin therapy (men n = 7; women n = 3; age
59.5 – 17.6 years; Table 1) who were hospitalized to achieve
optimal glucose control. Two patients with type 1 diabetes mel-
litus and eight with type 2 diabetes mellitus received multiple-
dose insulin injection therapy. They were also treated with
biguanides (n = 4), sodium–glucose co-transporter 2 inhibitor
(n = 3), dipeptidyl peptidase-4 inhibitor (n = 2), glinides
(n = 1), a-glucosidase inhibitor (n = 1) and liraglutide (n = 1).
The ethics committees at Mito Medical Center, Tsukuba
University Hospital and Mito Kyodo General Hospital
approved this study, and written informed consent was
obtained from all patients to participate.
Laboratory studies proceeded on admission. Venous blood
glucose (BG) values were determined using the glucose oxida-
tion method. The enrolled patients underwent simultaneous 24-
h CGM using the iPro2 (Medtronic Inc., Northridge, PA, USA)
and FSL-Pro FGMS (Abbott Diabetes Care Inc., Alameda, CA,
USA) systems. A total of 10 patients measured ISFG using both
systems for 7 days. The FSL-Pro and iPro2 Enlite sensors were
applied to the upper arm on one side. The FSL-Pro and iPro2
Enlite sensors record ISFG every 15 and 5 min, respectively.
SMBG was carried out four times daily (before meals and at
bedtime) to calibrate ISFG determined using the iPro2. The
iPro2 and FSL-Pro recordings were aligned to obtain paired
glucose measures, and glucose values obtained from the FSL-
Pro were compared with the closest of those obtained using the
iPro2. The lag time was maintained at <2 min between iPro2
and FSL-Pro glucose values. Unpaired iPro2 glucose values
were discarded. Likewise, glucose values from the two systems
were also compared with the closest capillary BG value deter-
mined by SMBG.
The consistency of glucose values provided by FSL-Pro or
iPro2 with SMBG in the clinically meaningful areas from A to
E was evaluated using Parkes error grid analysis8,9. Because
boundaries are stricter for the type 1 diabetes mellitus than the
type 2 diabetes mellitus version of the Parkes error grid, the
stricter type 1 diabetes mellitus version should therefore be
the analytical method of choice for accurate assessments9. Thus,
the present study applied the type 1 diabetes mellitus version
for the combined population of type 1 and type 2 diabetes mel-
litus. Absolute differences (AD) and absolute relative differences
(ARD) against the SMBG value for the FSL-Pro and iPro2 were
determined as follows:
AD (mg/dL) ¼ jFSL-Pro (iPro2) SMBGj
ARDð%Þ ¼ 100 jFSL-Pro (iPro2) SMBGj=SMBG:
The median AD and median ARD were calculated for each
patient.
Agreement between FSL-Pro and iPro2 glucose values was
checked based on linear correlations. Differences in glucose val-
ues between the two systems were calculated and plotted in
accordance with glucose values measured using the iPro2. The
AD and ARD between FSL-Pro and iPro2 were also deter-
mined based on glucose values provided by iPro2 for a head-
to-head comparison:
AD (mg/dL) ¼ jFSL-Pro ðiPro2Þj
ARDð%Þ ¼ 100 jFSL-Pro - iPro2j=iPro2:
The median AD and median ARD were calculated for each
patient.
Continuous variables with normal distribution are presented
as means (standard deviation), and non-normal variables are
expressed as medians (interquartile range). Pairs of groups were
compared using the Wilcoxon signed-rank test. The Kruskal–
Wallis test was applied for multiple comparisons, and statisti-
cally signiﬁcant results of multiple comparisons were individu-
ally compared using Mann–Whitney U-tests with Bonferroni
correction. Linear correlations were checked using the
Table 1 | Patients’ characteristics at baseline
Parameter
Men/women 7/3
Age (years) 59.5 – 17.6
BMI 25.3 – 4.0
T1DM/T2DM 2/8
BG (mg/dL) 410.3 – 122.0
HbA1c (%) 13.7 – 2.5
Insulin (U/day) 35.8 – 22.3
Biguanides 4
SGLT2i 3
DPP4i 2
Glinides 1
a-GI 1
Liraglutide 1
a-GI, a-glucosidase inhibitor; BG, blood glucose; BMI, body mass index;
DPP4i, dipeptidyl peptidase-4 inhibitor; HbA1c, hemoglobin A1c; SGLT2i,
sodium–glucose co-transporter 2 inhibitor; T1DM, type 1 diabetes melli-
tus; T2DM, type 2 diabetes mellitus.
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Spearman rank correlation coefﬁcient. A value of P < 0.05 was
considered signiﬁcant. The Bonferroni correction yielded a
threshold of signiﬁcance for uncorrected P-values of 0.017
instead of 0.05. Data were statistically analyzed using SPSS
version 23 (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 10 of the enrolled patients with diabetes mellitus
(type 1, n = 2; type 2, n = 8) were hospitalized to achieve opti-
mal plasma glucose control. Values for BG and hemoglobin
A1c were 410.3 – 122.0 mg/dL and 13.7 – 2.5%, respectively
(Table 1). All patients required multiple-dose insulin injection
therapy, and the mean insulin dose was 35.8 – 22.3 units per
day.
The accuracy of the FSL-Pro and iPro2 was initially com-
pared with SMBG. Parkes error grid analyses showed that 92.9
and 7.1% of glucose values generated by the FSL-Pro fell within
areas A and B, respectively, and that 96.3, 2.8 and 0.9% of
those measured using the iPro2 fell within areas A, B and C,
respectively (Figure 1a,b).
Glucose values generated by the FSL-Pro and iPro2 were
compared with the closest capillary BG values determined using
SMBG (Table 2). The overall glucose values were signiﬁcantly
decreased by 2.6% for the FSL-Pro compared with the SMBG.
In contrast, overall glucose values did not signiﬁcantly differ
between the iPro2 and SMBG. Although the glucose values
were decreased by 4.1% for the FSL-Pro compared with SMBG
during euglycemia (SMBG 70–180 mg/dL), those determined
using the iPro2 were increased by 2.1% compared with SMBG.
Glucose values were comparable among these three systems
during hyperglycemia (>180 mg/dL). Because just two glucose
values were determined using SMBG as <70 mg/dL, statistical
analyses were not possible during hypoglycemia <70 mg/dL.
The overall median ARD versus SMBG for the FSL-Pro and
iPro2 were 8.1% (3.9–12.7%) and 5.0% (2.6–9.1%), respectively
(Table 3). Although the median ARD signiﬁcantly differed
overall between the FSL-Pro and the iPro2, the accuracy of
both systems compared with SMBG was acceptable. The overall
median AD against SMBG was signiﬁcantly higher for the FSL-
Pro than the iPro2 (Table 3). The median ARD and AD were
also assessed in terms of degrees of glycemia. Table 3 shows
that the median ARD and AD were signiﬁcantly higher for the
FSL-Pro than the iPro2 during euglycemia and hyperglycemia.
Because just two glucose values were determined by SMBG as
being <70 mg/dL, statistical analyses were not possible during
hypoglycemia. In addition, whereas values determined by
SMBG indicated hypoglycemia, those determined using the
iPro2 were normal, which would lead to higher ARD and AD
for the iPro2 than the FSL-Pro during hypoglycemia (ARD
66.1 vs 6.3; AD 42.0 vs 4.0; Table 3).
We then compared glucose values determined using the FSL-
Pro with the closest of those generated using the iPro2 and
found a close correlation between them (q = 0.96, P < 0.01) in
a pooled analysis of 5,555 paired values from the 10 patients
(Figure 2a). Notably, 65.3% of overall glucose values were lower
for the FSL-Pro than the iPro2. The difference between FSL-
Pro and iPro2 was more pronounced when lower glucose val-
ues were determined by the iPro2 (Figure 2b). The difference
in the two systems weakly, but signiﬁcantly, correlated posi-
tively with glucose values determined using the iPro2
(q = 0.21, P < 0.01).
The iPro2 generated glucose values of 0.3, 48.0 and 51.7% in
hypoglycemia, euglycemia and hyperglycemia (iPro2 <70, 70–
180 and >180 mg/dL, respectively; Table 4). Overall median
glucose values were signiﬁcantly decreased by 3.3% when mea-
sured using the FSL-Pro compared with the iPro2 (177.0
[133.0–228.0] vs 183.0 [145.0–230.0] mg/dL, P < 0.01; Table 4).
In detail, glucose values were signiﬁcantly decreased by 8.3 and
1.3% according to the FSL-Pro during euglycemia and hyper-
glycemia, respectively, whereas they were signiﬁcantly increased
by 58.5% according to the FSL-Pro compared with the iPro2
during hypoglycemia.
The overall median ARD between the two systems was 6.5%
(3.6–11.5%, P < 0.01). The median ARD between glycemic val-
ues obtained using the two systems differed the most and least
under conditions of hypoglycemia and hyperglycemia, respec-
tively (Figure 3a). The median ARD in hypoglycemia was
500
400
300
200
100
0
500
(a)
(b)
E D C B
B
C
D
A
A
E D C B
B
C
D
A
A
400
300
200
100
0
500400300200
FS
L-
Pr
o 
(m
g/
dL
)
iP
ro
2 
(m
g/
dL
)
SMBG (mg/dL)
1000
500400300200
SMBG (mg/dL)
1000
Figure 1 | Parkes error grid analyses. Clinical validity of (a) the FreeStyle
Libre Pro (FSL-Pro) and (b) iPro2 assessed by Parkes error grid analyses.
SMBG, self-monitoring glucose monitoring.
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much higher than that of euglycemia or hyperglycemia (57.1%
[17.1–76.7%] vs 6.7% [4.1–12.9%] vs 6.2% [3.0–10.5%]). The
overall median AD between the two systems was 12.0 (6.0–
22.0 mg/dL, P < 0.01). Consistent with the difference between
two systems (Figure 2b; Table 4), the median AD was also
higher in hypoglycemia than in euglycemia or hyperglycemia
(27.0 [15.0–32.0] vs 9.0 [6.0–18.0] vs 14.0 [7.0–24.0] mg/dL;
Figure 3b).
DISCUSSION
Patients who are unaware of having nocturnal hypoglycemia,
have signiﬁcant glucose variability or have discrepancies
between hemoglobin A1c and SMBG should use CGMS6,10, as
it improves hemoglobin A1c without increasing the risk of
hypoglycemia compared with SMBG alone11,12. New methods
of CGMS have recently been developed7, and the iPro2 CGMS
is widely used in Japan. The FSL-Pro FGMS was recently
approved and will become more popular in clinical practice,
replacing iPro2 CGMS. Herein, we assessed FSL-Pro FGMS
and iPro2 CGMS in a head-to-head comparison, and found
that both were clinically acceptable. We also identiﬁed a close
correlation between FSL-Pro and iPro2 glucose values, although
a difference in glucose values between the two systems was pro-
nounced in hypoglycemia. Agreement between the two systems
determined by ARD was the worst and best during hypo-
glycemia and hyperglycemia, respectively.
Parkes error grid analysis showed that 92.9 and 7.1% of all
glucose values determined by the FSL-Pro fell into areas A and
B, respectively, which was consistent with the outcomes
reported by Bailey et al.13. In addition, 96.3, 2.8 and 0.9% of
glucose values determined by the iPro2 also fell into areas A, B
and C, respectively, suggesting that both systems are clinically
acceptable.
Table 2 | Comparison of glucose values generated using FreeStyle Libre Pro and iPro2 with closest values generated using self-monitoring blood
glucose
n SMBG (mg/dL) FSL-Pro (mg/dL) iPro2 (mg/dL)
Overall 323 189.0 (152.0–248.0) 184.0 (144.0–249.0)*,** 195.0 (151.0–247.0)
Hypoglycemia 2 63.5 67.5 105.5
Euglycemia 141 145.0 (123.5–165.5) 139.0 (115.0–158.5)*,** 148.0 (125.0–167.0)***
Hyperglycemia 180 238.0 (207.3–278.8) 239.5 (201.0–279.0) 238.0 (206.0–272.0)
Glycemia is classified based on the glucose values determined by self-monitoring blood glucose (SMBG). Data are expressed as medians (interquar-
tile range). *P < 0.01 versus SMBG. **P < 0.01 versus iPro2. ***P < 0.01 versus SMBG. Values were compared using Wilcoxon signed-rank test with
Bonferroni correction. FSL-Pro, FreeStyle Libre Pro.
Table 3 | Median median absolute relative differences and median
absolute differences between FreeStyle Libre Pro and self-monitoring
blood glucose, and between iPro2 and self-monitoring blood glucose
FSL-Pro iPro2
Median ARD (%)
Overall 8.1 (3.9–12.7)* 5.0 (2.6–9.1)
Hypoglycemia 6.3 66.1
Euglycemia 8.9 (4.1–14.0)* 5.6 (2.8–10.3)
Hyperglycemia 7.8 (3.6–12.4)* 4.4 (2.5–8.1)
Median AD (mg/dL)
Overall 15.0 (7.0–25.0)* 10.0 (5.0–17.0)
Hypoglycemia 4.0 42.0
Euglycemia 13.0 (6.0–19.0)* 8.0 (4.0–14.0)
Hyperglycemia 18.0 (9.0–30.0)* 12.0 (6.0–19.8)
Data are expressed as medians (interquartile range). *P < 0.01 versus
iPro2. Wilcoxon signed-rank test was used for a comparison. AD, abso-
lute differences; ARD, median absolute relative differences; FSL-Pro, Free-
Style Libre Pro.
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Figure 2 | Agreement between the FreeStyle Libre Pro (FSL-Pro) and
iPro2. (a) FSL-Pro versus iPro2. (b) Differences in glucose values
between systems plotted according to glucose values generated using
iPro2. (a,b) Linear correlations were confirmed using the Spearman rank
correlation coefficient.
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While the glucose values were signiﬁcantly decreased for
FSL-Pro compared with SMBG, the iPro2 generated signiﬁ-
cantly increased glucose values compared with SMBG during
euglycemia (Table 2). In contrast, glucose values generated
using the FSL-Pro and iPro2 were comparable with those gen-
erated by SMBG during hyperglycemia. As a result, overall glu-
cose values were signiﬁcantly more decreased for the FSL-Pro
than SMBG. Overall glucose values did not signiﬁcantly differ
between the iPro2 and SMBG. The accuracy of these two sys-
tems was compared with that of SMBG as median ARD
(Table 3). Although the median ARD was signiﬁcantly higher
for the FSL-Pro than the iPro2, both systems were accurate
with regard to SMBG7, except in the hypoglycemic range,
which was barely conﬁrmed by SMBG in the present study. A
comparison of the FSL with capillary BG found a mean ARD
(MARD) of 8.3% in patients with type 1 and type 2 diabetes
mellitus14, which was similar to the present outcomes. The
results from the Parkes error grid analysis and the median
ARD showed that both systems can contribute to the appropri-
ate self-management of diabetes in clinical practice. We used
capillary BG provided by SMBG rather than venous BG to
assess ARD because of the practical limitations of frequent
blood collection. Furthermore, SMBG provided more reference
points and represented real-life accuracy during daily patient
use. One report has described that SMBG can serve as the pri-
mary comparator for FGMS performance evaluation13. Many
studies have used the MARD to determine the accuracy of
FGMS and CGMS13–18. However, we applied median ARD
instead of MARD, because the distribution of the glucose values
measured in the present study was not normal. The average
reported ARD is 0.8% 9 MARD7.
We then found a close correlation in overall glucose values
between the FSL-Pro and iPro2. The median overall glucose
value was decreased by 3.3% when measured by the FSL-Pro
compared with the iPro2 (Table 4). Notably, 65.3% of overall
glucose values were lower for the FSL-Pro than the iPro2. Glu-
cose values were signiﬁcantly more deceased for the FSL-Pro
compared with the iPro2 during euglycemia and hyperglycemia,
and signiﬁcantly more increased for the FSL-Pro than the iPro2
during hypoglycemia. The difference in glucose values between
the two systems was more pronounced at lower glucose values
determined using the iPro2 (Figure 2b; Table 4). The median
AD between the two systems was signiﬁcantly higher in hypo-
glycemia than in euglycemia and hyperglycemia in the present
study, which raises concerns about direct comparisons of abso-
lute glucose values provided by these two systems during hypo-
glycemia. Although few comparisons of FSL-Pro and iPro2 have
been reported, one study found signiﬁcantly lower glucose values
generated by the FSL than the iPro2 during oral glucose loading
tests of outpatients with type 1 and type 2 diabetes mellitus14.
Glucose values provided by CGMS might be inaccurate dur-
ing hypoglycemia, and the MARD reportedly varies in terms of
glucose levels19,20. The median ARD between FSL-Pro and
iPro2 in hypoglycemia was much higher than that in either
euglycemia or hyperglycemia in the present study, indicating
that the two systems did not closely agree during hypoglycemia.
In contrast, the median ARD was optimal during hyper-
glycemia. The present study ﬁndings are in line with the
recently published accuracy of FSL CGMS14–17. The MARD
between FSL and Dexcom G4 Platinum (Dexcom Inc., San
Diego, CA, USA) CGMS was higher in hypoglycemia than in
Table 4 | Comparison of glucose values between FreeStyle Libre Pro
and iPro2
n FSL-Pro (mg/dL) iPro2 (mg/dL)
Overall 5,555 177.0 (133.0–228.0)* 183.0 (145.0–230.0)
Hypoglycemia 16 74.5 (60.8–76.8)* 47.0 (40.5–65.0)
Euglycemia 2,669 132.0 (108.0–154.5)* 144.0 (120.0–162.0)
Hyperglycemia 2,870 225.0 (196.0–266.0)* 228.0 (202.0–265.0)
Glycemia is classified based on the glucose values determined by the
iPro2. Data are expressed as medians (interquartile range). *P < 0.01
versus iPro2. Wilcoxon signed-rank test was used for a comparison.
FSL-Pro, FreeStyle Libre Pro.
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either euglycemia or hyperglycemia15,17. The MARD of several
devices, including the FSL, compared with venous or capillary
BG are also higher in hypoglycemia than in euglycemia or
hyperglycemia14,16,17. Therefore, care is required if CGMS or
FGMS is applied to patients who are frequently unaware of
being hypoglycemic, or who have nocturnal hypoglycemia. Low
glucose values measured by these systems should routinely be
conﬁrmed by SBMG. Furthermore, even if these systems do
not indicate hypoglycemia, SMBG should proceed if symptoms
of hypoglycemia arise.
The present study was limited by the small number of patients
and the lack of a gold standard against which to measure plasma
glucose values. Furthermore, because SMBG determined that just
two glucose values were <70 mg/dL, the accuracy of the two sys-
tems could not be compared with capillary BG during hypo-
glycemia. Nevertheless, values determined using the FSL-Pro and
iPro2 systems agreed in hospitalized patients.
In conclusion, both the FSL-Pro and iPro2 systems are clini-
cally acceptable, but glucose values tended to be lower when
generated using the FSL-Pro than the iPro2. In addition, values
generated by these two systems did not closely agree during
hypoglycemia. These data should be helpful when considering
therapeutic regimens based on glucose values provided by the
FSL-Pro and iPro2 systems.
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